Scienture Holdings, Inc. SCNX
3.20 USD +0.09 (+2.89%)
At closeNov 9, 2026, 4:00 PM EST
3.20 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
3.03 Day range 3.21
2.64 52-week range 19.48
- YTD
- -74.90%
- 1 year
- -82.59%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
benzinga.com Maxim Group Maintains Buy on Scienture Holdings, Adjusts Price Target To $6 (reverse stock split 1:25) Maxim Group analyst Naz Rahman maintains Scienture Holdings (NASDAQ:SCNX) with a Buy, adjusts target to $6 from $37.5 (reverse stock split 1:25).
benzinga.com Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027 Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
benzinga.com SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and…
benzinga.com EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
benzinga.com EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions Three U.S. pediatric hospitals added Scienture's hypertension drug Arbli to their formularies, boosting institutional reach.
benzinga.com Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
benzinga.com Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened Scienture Holdings shares tumble 19% after hours following a newly announced 1-for-25 reverse stock split.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…
benzinga.com SCIENTURE To Provide REZENOPY To Addiction Treatment Centers Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Modular Medical (NASDAQ:MODD) shares increased by 11.3% to $3.14 during Wednesday's pre-market session. The market value of their outstanding shares is at $22.9 million. InnovAge Holding…
benzinga.com Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of…
benzinga.com EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U.S. wholesale orders.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…
benzinga.com Why WD-40 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket WD-40 Co (WDFC) shares rise sharply in pre-market trading after reporting better-than-expected third-quarter financial results.
benzinga.com Scienture Holdings Stock Jumps Over 20% Pre-Market: Here's Why Scienture Holdings shares jumped 23.54% overnight after the company completed manufacturing inventory for the commercial launch of REZENOPY.- benzinga.com Scienture To Begin Shiptments Of REZENOPY Nasal Spray 10mg To U.S. Pharmaceutical Wholesalers Later This Month The Company expects REZENOPY™ to become commercially available for purchase in August. The Company is working with its wholesale distribution partners in preparation for nationwide commercial…
- benzinga.com Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel Partnerships The Company recently secured additional payor coverage representing approximately 12.5 million incremental covered lives, including expanded access through Medicare Part D supplement plans and other…
- benzinga.com FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose
benzinga.com EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch Scienture expands Rezenopy access through a major health plan ahead of launch, adding coverage for more than 100 million lives.
benzinga.com EXCLUSIVE: SCIENTURE Secures Formulary Coverage For REZENOPY; Commercial Launch Planned For Mid-July 5,000+ Healthcare Facilities Reached ThroughGPO Agreements, Covering ~60% of Institutional GPO MarketU.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units…- benzinga.com Scienture Holdings Q1 EPS $(0.08) Beats $(0.22) Estimate, Sales $56.325K Up From $10.258K YoY Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.22) by 63.64 percent. This is a 75.76 percent increase over losses of…
- benzinga.com SCIENTURE HOLDINGS Secures $11M In Non-Dilutive Debt Financing Through Note Purchase Agreement With Institutional Investor Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatmentFinancing also drives…
benzinga.com USPTO Issued SCIENTURE HOLDINGS U.S. Patent No. 12,605,365, Titled "Losartan Liquid Formulations and Methods of Use," U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension
benzinga.com Scienture Awarded $950K U.S. Department Of Veterans Affairs Pharmaceutical Supply Contract, Pharmaceutical Preparation Manufacturing https://sam.gov/opp/cd98e3d515624c65afe83187b80993a7/view- benzinga.com SCIENTURE HOLDINGS Gets 180‑Day Nasdaq Extension; Compliance Deadline Now October 12 SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025 Scienture reports 216% revenue growth in 2025, driven by Arbli uptake, patent wins, and expanded healthcare access across the US.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market Scienture signs agreements expanding Rezenopy naloxone for opioid overdose access to 5,000 US institutions and first responders.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Maxim Group Initiates Coverage On Scienture Holdings with Buy Rating, Announces Price Target of $1.5 Maxim Group analyst Naz Rahman initiates coverage on Scienture Holdings (NASDAQ:SCNX) with a Buy rating and announces Price Target of $1.5.
- benzinga.com SCIENTURE HOLDINGS Reaffirms Plan To Commercially Roll Out REZENOPY In Q2 SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers…
- benzinga.com Scienture Expands Access to ARBLI and Prepares for Launch of REZENOPY in 2026 SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emergency Opioid Overdose Treatment New US patent strengthens protection for Rezenopy, the FDA-approved 10 mg naloxone nasal spray.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Scienture Advances Commercial Launch Of FDA-Approved REZENOPY Following Exclusive U.S. Commercialization Agreement U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annuallyCOMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Why Is Scienture Stock Gaining Today? Scienture stock is climbing after the company partnered with BlinkRx to expand national access to its new FDA-approved liquid losartan therapy, Arbli.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Scienture Holdings Q3 EPS $(0.19) Up From $(1.34) YoY, Sales $590.050K Up From $64.861K YoY Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.19) per share. This is a 85.82 percent increase over losses of $(1.34) per share from the same period last year. The company reported…
benzinga.com EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction Scienture's Q3 revenue surged on Arbli sales, debt dropped, and cash rose to $8 million ahead of its planned Rezenopy launch in early 2026.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session